Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Roth

Showing results (91-100 of 396) with videos related to

Pageof 40
Sort By:
Chronobiology International|July 25, 2012
Circadian phase, sleepiness, and light exposure assessment in night workers with and without shift work disorderValentina Gumenyuk, Thomas Roth, Christopher L Drake
Journal of Clinical Psychopharmacology|April 11, 2014
The effects of armodafinil on objective sleepiness and performance in a shift work disorder sample unselected for objective sleepinessRyan Howard, Thomas Roth, Christopher L Drake
Depression and Anxiety|December 9, 2003
Insomnia causes, consequences, and therapeutics: an overviewChristopher L Drake, Timothy Roehrs, Thomas Roth
Sleep Medicine Reviews|January 30, 2013
Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medicationsAndrew D Krystal, Elliott Richelson, Thomas Roth
Sleep|August 2, 2014
Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomniaChristopher L Drake, Vivek Pillai, Thomas Roth
The American Journal of Managed Care|December 6, 2007
The state of insomnia and emerging trendsThomas Roth, Meg Franklin, Thomas J Bramley
Sleep & Breathing = Schlaf & Atmung|September 18, 2007
Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apneaThomas Roth, Gregory A Rippon, Sanjay Arora
Sleep|September 22, 2005
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environmentThomas Roth, Charlene Stubbs, James K Walsh
Sleep & Breathing = Schlaf & Atmung|February 13, 2007
Safety of ramelteon in individuals with mild to moderate obstructive sleep apneaMeir Kryger, Sherry Wang-Weigand, Thomas Roth
Sleep Medicine|September 11, 2007
Vulnerability to insomnia: the role of familial aggregationChristopher L Drake, Holly Scofield, Thomas Roth
Pageof 40

Showing results (91-100 of 396) with videos related to

Sort By:
Pageof 40
Chronobiology International|July 25, 2012
Circadian phase, sleepiness, and light exposure assessment in night workers with and without shift work disorderValentina Gumenyuk, Thomas Roth, Christopher L Drake
Journal of Clinical Psychopharmacology|April 11, 2014
The effects of armodafinil on objective sleepiness and performance in a shift work disorder sample unselected for objective sleepinessRyan Howard, Thomas Roth, Christopher L Drake
Depression and Anxiety|December 9, 2003
Insomnia causes, consequences, and therapeutics: an overviewChristopher L Drake, Timothy Roehrs, Thomas Roth
Sleep Medicine Reviews|January 30, 2013
Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medicationsAndrew D Krystal, Elliott Richelson, Thomas Roth
Sleep|August 2, 2014
Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomniaChristopher L Drake, Vivek Pillai, Thomas Roth
The American Journal of Managed Care|December 6, 2007
The state of insomnia and emerging trendsThomas Roth, Meg Franklin, Thomas J Bramley
Sleep & Breathing = Schlaf & Atmung|September 18, 2007
Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apneaThomas Roth, Gregory A Rippon, Sanjay Arora
Sleep|September 22, 2005
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environmentThomas Roth, Charlene Stubbs, James K Walsh
Sleep & Breathing = Schlaf & Atmung|February 13, 2007
Safety of ramelteon in individuals with mild to moderate obstructive sleep apneaMeir Kryger, Sherry Wang-Weigand, Thomas Roth
Sleep Medicine|September 11, 2007
Vulnerability to insomnia: the role of familial aggregationChristopher L Drake, Holly Scofield, Thomas Roth
Pageof 40